Legislative and regulatory tracking, explained.

What legislative tracking is: reading every change to the rules a medicine lives under

One bill's night: from committee vote to the 9 am meeting

1. The text changesThe Senate Finance Committee adopts a manager's amendment to S. 9187 and votes 19 to 8 at 9:40 pm on October 6, 2026.
2. Someone finds itA feed or an alert says the bill moved. It rarely says what moved inside the bill.
3. Someone reads and scores itA person, or a system, compares the versions, sees two new sections and traces them to medicines. This is the step this guide is about.
4. The lead is toldAn alert with the changed text goes to the vice president, and market access is copied, before 7 am.
5. The company respondsStaff meetings, comments, a filing plan. Any contact with an official goes in the record for the next lobbying report.

The bill, the vote, the committee members and the times in this example are fictional.

Why following drug pricing bills surprises people new to it

Manager's amendment, redline, delinking, 340B: four terms this work runs on

Fourteen terms are defined in the one-page summary.

Bills, rules, dockets, boards, hearings and court orders: six kinds of source a pharma policy team monitors

In short"Legislative tracking" sounds like bills. In drug policy the bill is one of six kinds of source, each with its own publisher, format and pace. A watch list, the set of sources a team checks, has to cover all six, or its gaps stay invisible until something lands.

Formats are our description of typical documents, and they vary. CMS is the Centers for Medicare & Medicaid Services, HRSA the Health Resources and Services Administration, which runs 340B, and FTC the Federal Trade Commission. A docket is the public file an agency or court keeps on a rule or case. Presidential proclamations belong on the list too: a tariff proclamation reaches the same people as a rule.

Most favored nation pricing, in the grid, links what Medicare pays for a drug to what other countries pay;12 biosimilars are medicines highly similar to an approved biologic, a medicine made from living or natural sources.14 This grid is why teams that buy a bill feed still miss things. A price cap may start with a board's agenda, turn on a federal court's order and end in a legislature's 2027 session. The issue is the unit that matters, and a bill number is only one place an issue can live.

130,120 state bills in six months: how much text a state legislative tracking team faces

In shortTracking volume is high in the states and fell at the federal level in 2025. Most introduced bills never pass, so a raw count overstates the work. The hard part is the small share that moves and reaches a medicine, and no public source says how many that is for a given company.

The same report counts 15,951 of those 130,120 bills as enacted by June 30, 2025.1 Over the same months Congress introduced 6,638 and enacted 28. A second tracker's recap, quoted by its own staff in September 2025, puts 2025 state introductions at over 135,500, a useful reminder that the often-quoted 130,000 covers only part of the year and that each tracker counts its own way.15

Federal rulemaking moved the other way. One tally of the Federal Register counts 60,917 pages in 2025, against a record 106,109 in 2024; another counts 61,584, because counts differ by date and method.16,17 Fewer pages did not mean less to read for drug makers. One 2026 proclamation reaches most patented drug imports, and one proposed rule reaches most 340B hospitals paid under Medicare's outpatient system.10,11,18

Proposed, ordered reported, enacted, in effect: how to read a bill's or rule's status without overstating it

In shortThe easy mistake in a policy brief is overstating a stage, meaning how far a bill or rule has gone. A committee vote is an order to report the bill to the floor, a passed chamber is half a law, a proposed rule binds nobody, and a final rule can be blocked by a court. Say which of these you mean, and date it.

The Congressional Research Service describes the Senate step this way: the committee "moves to order the measure reported", and the measure is later reported to the Senate by the chair.7 Trackers and news items often say "reported" on the night of the vote. For a brief, "ordered reported 19 to 8" is the accurate wording until the filing appears.

Why a passed bill number can miss the law: provisions travel between vehicles

A vehicle is the bill that carries a provision to a vote. Spending bills and year-end packages carry many provisions that began elsewhere. Public Law 119-75, the Consolidated Appropriations Act, 2026, carries limits on PBM pay under Medicare Part D, the prescription drug benefit,19 in section 6224, and rules for group health plans in sections 6701 and 6702.3 A team tracking only stand-alone PBM bills could have watched each of them stall while the substance became law. Good tracking follows the provision by its language and by what it does.

Rules, guidance and notices carry different weight

Status as of November 3, 2026. A summary for a reader's orientation, and our own reading of each document.

PBM reform, Medicare negotiation, most favored nation pricing, 340B, price caps, tariffs: where each stood on November 3, 2026

In shortSeveral drug policy questions a reader might think are open were settled in 2026, and several that sound settled are still proposed. Every date below is a snapshot. Bills and rules move, so check the current text before relying on any of it.

PBM reform is federal law, with rules still to come

Enacted February 3, 2026. For Part D plan years from January 1, 2028, section 6224 limits PBM income to bona fide service fees. A fee counts if it is a flat dollar amount consistent with fair market value and tied to services performed.3

For group health plans, sections 6701 and 6702 apply to plan years beginning 30 months after enactment. Section 6702 amends ERISA, the federal law that sets minimum standards for most private-sector health and retirement plans.25 It requires 100 percent of rebates and fees from drug makers to be remitted to the plan, with bona fide service fees left out.3

Proposed: CMS-4214-P, published October 20, 2026, would set out how fair market value works.20 Also proposed: the FTC's consent orders with two PBMs, from February 4 and July 14, 2026. FTC's page listed no final order on November 3, 2026.24 States keep legislating. One trade report names Arkansas, California, Iowa, North Carolina and Texas among those with major 2026 activity, with preemption litigation, suits over whether federal law overrides state law, ongoing.26

Medicare drug price negotiation: third-cycle prices due by November 30

Under the Inflation Reduction Act (IRA), Medicare negotiates the prices of selected drugs in rounds called cycles. CMS has posted negotiated prices for 10 drugs in effect from January 1, 2026 and 15 from January 1, 2027.13 The third cycle covers 15 drugs payable under Part B or Part D plus one drug selected for renegotiation.13,27

Under CMS's guidance, the third-cycle negotiation period ends November 1, 2026, with the last day to accept or reject an offer on October 31, and any prices published by November 30.28 CMS's page listed no third-cycle prices on November 2.13 The 2029 cycle is the first to run by regulation, and that regulation, CMS-4215-P, was still proposed on November 3, with the final version under review at the White House budget office since September 9.29,30

Most favored nation pricing: one final rule, narrowed, and a suit

Most favored nation pricing links what Medicare pays for a drug to what other countries pay.12 GLOBE, the Global Benchmark for Efficient Drug Pricing model, does this for Part B, the part of Medicare that generally covers drugs a provider gives you, such as infusions.12,31 CMS published the final rule on October 2, 2026, effective November 30. Its five performance years run from April 1, 2027 through March 31, 2032. CMS narrowed it from the proposal and expects only four manufacturers in the model.21,12

A suit challenging it was filed in federal court in Washington, D.C., on October 7, and we found no ruling on it by November 3.32,33 The companion Part D model, GUARD, is not final: its final rule was still under review at the White House budget office on November 3, 2026.30

340B: state laws, split courts, and a proposed Medicare payment cut

About 21 states had laws barring limits on contract pharmacy delivery by late 2025, 13 of them enacted that year.34,35 Courts disagree (see section 10).

HRSA's rebate pilot notice sets plans effective January 1, 2027 for selected drugs that made up less than 5.5% of 340B sales in 2025.8 HRSA approved 10 drug companies for the pilot on October 1, and a suit filed October 9 in federal court in Maine seeks to stop it; we found no ruling by November 3.23

CMS's outpatient proposal for calendar year (CY) 2027 would pay for 340B drugs at the average sales price minus 33.4%.10 Its final rule is not out: it was still under review at the White House budget office on November 3, 2026, so check before you cite it.30

Prescription drug affordability boards: limits set, and one stopped in court

At least ten states had active boards in August 2025, and at least five (Colorado, Maryland, Minnesota, Oregon and Washington) can set an upper payment limit, the most an in-state payer may pay.4 Colorado's limit on Enbrel, $600 per 50 mg unit from January 1, 2027, was the first.4 A federal judge in Denver blocked it by preliminary injunction, an order that holds it back while the case continues, on July 1, 2026. An appeal is pending at the Federal Circuit, a national appeals court for specialized cases.5,6,36

Maryland's board approved a limit on Jardiance on April 13 and revised it May 18, 2026, and voted for one on Ozempic that May. State and local government entities may begin applying them from January 1, 2027, and the board's page says no Maryland limit is active yet.37,38

Tariffs: in effect since summer, with generics left out

The April 2, 2026 proclamation rests on Section 232, the law that lets a President adjust imports that threaten national security. It applies from July 31, 2026 for companies in its Annex III and from September 29, 2026 for others.11 Generics and biosimilars are outside it "at this time", and the Commerce Department is to advise the President on them within a year.11

A presidential social media post of July 21, 2026 described tariffs on generics after two years at zero; we found no signed proclamation for it.39 Rates depend on the company's onshoring and pricing agreements and on the country of origin, so the path to one medicine runs through its supply chain.11 The text we read sets no product-by-product request window.

Patents, biosimilars and patient costs: drafts, bills and state bans

The Senate passed a bill capping patents asserted against a biosimilar at 20 on July 11, 2024, and it went no further in that Congress.40 A similar bill, S. 1041, passed the Senate on July 21, 2026 and is held at the House desk.41 One trade report said on August 26, 2026 that FDA's recommendations that would drop switching studies "remain in draft form".42 Switching studies are extra studies some developers have run for biosimilars licensed as interchangeable.43

On patient costs, an August 2026 news count has 26 states, DC and Puerto Rico restricting copay accumulators, which keep manufacturer assistance from counting toward a deductible; the laws vary in scope.44

Comment deadlines at CMS, FDA, the FTC and state boards: the windows that close once

In shortA comment period is the public's chance to put evidence in the record. Medicare rules get at least 60 days by statute. State boards and FTC orders can run about 30. A comment filed after the close may be ignored, and a court reviewing the rule looks at the record that was built.

For Medicare, the statute calls for "a period of not less than 60 days for public comment".46 The 56 days above counts from Federal Register publication; rules usually go on public display first. Boards set their own calendars, published on an agenda that may change between meetings. Maryland's board took comments on its draft limit regulations through March 30, 2026, then its calculations through April 6.37

Other dates a pharma policy calendar must hold

Consequences are our plain-language summary. Ask counsel about a specific deadline.

Which medicine does this bill reach? Working out exposure and an impact score, with numbers

In shortA provision reaches a medicine through a channel: Medicare Part D, Part B, commercial plans, 340B sites. If you know each medicine's channel mix, its share of sales through each of those routes, you can trace most provisions quickly. A score then ranks the reading, and it stays an opinion, with reasons a person can check.

Take the fictional Northwind Bio from the top of this page. It has three medicines, and market access keeps a table of where each one earns its money.

All fictional. Exposure is a fact a company keeps and reviews; nobody can read it from a bill's text.

A worked trace: three sentences of amendment, two medicines

How an impact score moves when a bill is amended: 54 to 86

Many teams rank items on a scale so the reading has an order. There is no standard method and no public benchmark. A common shape adds a few factors: how much the company cares about the issue, how exposed its products are, what new duty falls on it, how likely the item is to move, and how soon. Here is one bill before and after its amendment.

The useful part of a score is the reasons, each pointing at a passage. Effect on the company rose from 4 to 19 because of Sec. 4. Likelihood rose from 7 to 13 because of the vote. A reader can disagree with either number and know exactly what they disagree with.

LD-2 lobbying reports and issue codes: what tracking has to hand over each quarter

In shortCompanies that lobby Congress or senior federal officials file a quarterly LD-2 report listing the issues, the Houses and agencies contacted, the lobbyists and the spending. It does not list each contact, yet teams keep a contact log to fill it in accurately. State lobbying has its own separate filings.

The Lobbying Disclosure Act defines a lobbying contact as a communication to a covered official on a client's behalf about certain subjects, including legislation and rules.47 An in-house team must register once its lobbying expenses are expected to pass the threshold, $16,000 a quarter in the guidance read for this page, and an employee counts as a lobbyist once they make more than one contact and spend at least 20% of their time on lobbying activities.47

The issue codes a drug maker uses most, and one easy mistake

Codes as the House Clerk lists them.48 The guidance says filers "must use" TAR for tariff issues and "should use" TRD for "any other trade-related issues".47 A tracking list that files every tariff item under trade needs a second look with your compliance counsel. Which code fits a given contact is a legal judgment.

The guidance also warns against a common shortcut: a bill number alone is "not in itself a complete disclosure"; the report must say enough for a member of the public to see the specific issue.47 So a contact log needs the item, the section and a sentence on what was discussed, written when the memory is fresh. An item-level tracker that already holds the section is a natural place to start that record.

GAO also found 22% of quarterly reports listed lobbyists who had not fully disclosed prior federal jobs, and it reports 12,391 referrals to the US Attorney's Office in the District of Columbia for filing years 2016 to 2025, about 46% closed as in compliance by December 2025.49 Knowingly failing to fix a defect within 60 days of notice can bring a civil fine of up to $200,000, and knowing and corrupt non-compliance up to 5 years in prison.47

State law differs in thresholds, definitions and filing dates, and an approach to a state committee or a board's staff will not appear on an LD-2. Keep the two logs distinct even when one system holds both.

The spending behind these reports is large. Federal lobbying by the pharmaceutical and health products industry reached $457.3 million in 2025, about 15% more than 2024, according to OpenSecrets.50

Eight ways bill tracking and regulatory monitoring go wrong, and the check that catches each

In shortTracking usually fails quietly. The feed worked, an alert fired, and the wrong conclusion reached a vice president. No public dataset counts these errors, so what follows is a practitioner's list drawn from how the sources and rules work. Each failure has a simple check.

A state 340B law can stand in one circuit and fall in another: why policy tracking must follow the courts

In shortWhether a state law binds you can depend on which court hears it, and a ruling can change on rehearing. In 2026 this is the live story on state 340B contract pharmacy laws and on price caps. A list of enacted laws alone gives you the wrong map. A circuit is one of the 12 regional federal appeals courts.36

This is our tally of the American Hospital Association's list, and it counts decisions, some of them early motions, so it says little about final outcomes. It also comes from one side's trade group.

Federal appeals courts upheld such laws in cases from the Fifth and Eighth Circuits, while Fourth Circuit panels, the groups of usually three judges that decide appeals,36 ruled against West Virginia's and Maryland's in spring 2026. On May 28 the full court agreed to rehear both. Under that court's own rule the grant vacates, or cancels, the panel judgment and opinion, so the question there is open again.9,51,52,53 District courts have also blocked laws in North Dakota and Oklahoma.9 We found no decision from the full court by November 3, 2026.

The Colorado case makes the same point on price caps. The Congressional Research Service reported in January 2026 that the first suit was dismissed on procedural grounds in March 2025, a second was filed October 30, 2025, and no court had yet ruled on whether a board may set such a limit.4

On July 1, 2026 a federal judge blocked the limit while the case continues, and that order is on appeal at the Federal Circuit.5,6 A team that told its leads "Colorado's cap starts January 1, 2027" in February would need to correct that note in July. Maryland's board moved on limits of its own that same spring.37,38

What a late court catch does to a state plan

The practical result is a state-by-state status that changes without any legislature meeting. Contract pharmacy policies, demands for claims data and pricing models can each be lawful in one state and barred in the next, so the tracker has to hold the court's answer next to the statute, by state, with its date. Ask your counsel which reading applies to you. Tracking tells you the question exists.

What a missed amendment or comment deadline costs a drug maker, and why no one publishes the figure

In shortNo study prices a late read. The cost shows up elsewhere: a lead who walks into a meeting without the text, a comment that was never filed, a contract cycle planned on an old rule. A useful way to think about it: how much money the rule touches, multiplied by the days of response you lost.

Some of the sums at stake are public, such as the 340B purchases above.8 CMS put the third negotiation cycle's drugs at about 6% of Part B and D spending.27 Tariffs on covered patented imports start from a 100% base rate, with lower rates by country and agreement.11 When a rule of that size is in motion, a week's delay in telling the person who owns the response can matter a great deal, though no one can put a general price on it.

AI in policy monitoring: what it does well, what the rules say, and why every sentence still needs a citation

In shortLanguage models, the AI systems behind chat tools, read long text fast and can compare versions and draft summaries. Most drug industry AI rules do not reach this work, because it touches neither patients nor product quality. The real risk is a confident wrong statement, so the controls are quotations, citations and a person's confirmation.

What regulators say about AI in government affairs work: mostly nothing directly

• FDA's January 2025 draft guidance on AI for regulatory decisions covers drug and biological products and says it does not address AI used for operational efficiencies that do not affect patient safety, drug quality or the reliability of study results.54 A morning policy brief sits on that side of the line, and the draft is still a draft.
• Draft EU GMP Annex 22 applies to AI in manufacturing under good manufacturing practice (GMP), the minimum standards for how drugs are made.55 It says generative models "should not be used in critical GMP applications"; it remains a draft on November 3, 2026, EudraLex, the EU's body of medicines rules, lists no Annex 22, and EMA's June 2026 workshop report shows the drafters weighing a wider scope.56,57,58 This work is outside GMP.
• The EU AI Act's delayed high-risk dates, December 2, 2027 and August 2, 2028, are law through an amending regulation, the AI Omnibus.59 We do not read policy monitoring as a listed high-risk use; ask counsel if your use reaches further, for example into employment decisions.

The risk that matters: a confident, wrong answer about the law

A 2025 peer-reviewed study tested legal research tools built on retrieval, the method of pulling source passages before answering, and found they "each hallucinate more than 17% of the time". To hallucinate, in the authors' words, is to "make up false information".60 Those were legal research questions on commercial tools, so the figure is a warning for this work and cannot measure it.

In policy work a wrong statement might name the wrong effective date or call a proposal final. Three controls answer it: keep exact quotations next to any summary, cite every sentence to its passage, and let nothing reach a lead until a person has looked. In one vendor's 2025 survey of over 200 government affairs professionals, 53.8% said they use AI in their work and about 27% felt cautious and unsure, so this is a live question for teams.61

Who writes the morning policy brief: analysts, federal and state leads, market access and legal

In shortTeams are small. In one vendor's 2025 survey, 41% of respondents worked on teams of two to five, and 36.9% called themselves understaffed. The analyst reads and writes, the leads act, market access supplies exposure, legal reads sections, and operations files. On our illustrative estimate below, writing takes the largest share of the hours, and exposure questions wait on email.

Times are an illustration built from this guide's fictional case; nobody publishes a time study of this work.

Three ways teams run pharma policy monitoring

Teams can combine these. State coverage weighs heavily: 75% of respondents in the same 2025 survey named state legislatures a focus.61

S. 9187, from a 6 pm front page to a confirmed alert at 6:41 am

In shortThis is the example from the top of the page, inside the product. Agents, software workers that each do one job, read every source overnight, redline the new version, rescore it from 54 to 86 and draft an alert. Lena Ortiz, the director of policy analysis, reads the factors and passages and confirms. Nothing reaches Omar Haddad, the federal lead, before she does.

1

Tuesday's evening edition leads with Colorado

The home screen is laid out like a newspaper called The Morning Policy Brief. Each edition has a lead story, an index line and a right-hand rail of briefs by issue. At 6:00 pm on Tuesday, October 6, 412 documents have been read since 6:00 am, 96 of them on Northwind's issues.

The lead is a sample Colorado board hearing on Talvoren, impact 84, written comments due October 16. The alert has gone to Dana Okafor, the state lead, with Sam Patel from market access copied. The sweep is set for 11:00 pm.

2

The overnight sweep runs step by step

When the edition switches to Wednesday, the steps play in order. The Source Watcher finds that Senate Finance voted S. 9187 out 19 to 8 and that the Michigan House passed HB 9814 58 to 50: 1,284 documents read. The Provision Extractor redlines S. 9187: 2 sections inserted, 2 changed, 1 struck.

The Hearing Listener reads the executive session: 9 speakers, 3 mentions of Northwind's issues. The Impact Scorer moves S. 9187 from 54 to 86 and HB 9814 from 66 to 81. The Brief Writer drafts the alert and waits.

3

The 6:12 am front page sets the amendment as the lead

S. 9187 now leads: delinking extended to employer plans from 2028, a quarterly report of every rebate and fee manufacturers pay to PBMs, penalties up to $100,000 a day. The meter shows five factors, 24, 21, 19, 13 and 9, adding to 86, with a dark mark at each old value.

The index line reads 1,284 documents, 318 on Northwind's issues, 7 scored 80 or more, 3 waiting for confirmation, 5 briefs at 7:00 am.

4

The redline shows inserted, changed and struck text

The item page compares the March 12 text with the October 6 text. Sec. 3 on group health plans and Sec. 4 on manufacturer reporting are new. Sec. 2 moves from 2027 to 2028. Sec. 5 moves PBM reports to plan sponsors from semi-annual to quarterly. Sec. 6, a study on rebate pass-through, is struck.

The Provision Extractor quotes legal text in its provision record and keeps the passage with it. A highlighted line is one the score relies on.

5

Lena confirms 86, and the alert goes out with its citations

Lena reads each factor beside its passage and presses "Confirm 86 and send to Omar". The alert goes at 6:41 am, copy Sam Patel. It lists three changes that matter, says why, and carries a numbered citation on every sentence.

She could also adjust the score or set it to watch only. Contacts that follow are logged under issue codes PHA and MMM.

Design targets, labeled as such in the solution: a median of 38 minutes from a new version or vote to the lead's alert, confirmation included, and 8,940 documents read and scored in a week across Congress, 50 states and the agencies. These are design goals to measure in your own use. An estimate of about 11 analyst hours saved a week appears in Part C.

The provision-to-product path: how one amendment reaches two medicines and spares a third

In shortUnder the lead story, four columns trace each provision: in the text, what it changes, where the company feels it, and which product it reaches. A medicine it does not reach stays on the page, dashed, with the reason. This is the question leads ask first, answered before they ask it.

A state bill takes the same path: Michigan's 340B text and three medicines

The sample Michigan bill would bar limits on contract pharmacy delivery and claims-data conditions, with each package a separate violation. The path reads differently: Talvoren is the most exposed, at 31% of units through 340B sites, then Veltrimab at 12% through contract pharmacies and Dravenzo at 9% through specialty pharmacy. Any lead can switch the path to any story on the front page.

Five scored factors, each tied to a passage, with the old value marked

The right side of every item shows the score and why. Issue match 24 of 25 reads the issue's priority weight. Product exposure 21 of 25 reads the channel table. Effect on us 19 of 20 points to Sec. 4. Likelihood 13 of 20 points to the vote and the ranking member's remark. Timing 9 of 10 points to the effective date.

The small "was" figures show what each was before the amendment, so a reader can see that the issue did not change and the duty did. Scores are proposals until a person confirms them.

The Hearing Listener pulls the three moments that matter from a 2 hour 41 minute session: the chair on the amendment, the ranking member on floor time, and the clerk recording yeas 19, nays 8. It quotes speakers exactly and never infers a vote that was not recorded. All these speakers are fictional, and no real senator's position is shown.

The official text of a real hearing may come months later (2), so same-day reading needs committee video, captions or a licensed transcript. Agree on the source when you set it up, and check the quote against the record when it is published.

When she confirms, the record on the right says who did what and when. If Lena disagrees with a score, she moves it, and it is not saved without a reason. That reason goes on the audit trail and feeds the next scoring, and the agents' original score stays one click away. On Michigan HB 9814, for example, she might hold the 81 down if she thinks floor time is unlikely.

Tracked items, comment clocks, briefs per lead, the state desk and issue weights

In shortBeyond the front page, each screen answers one person's question. The items list says what moved, the clocks say what is due, the briefs say what each lead needs today, the issue grid says how each issue reaches each product, and the dashboard says how much was read and how fast.

Every bill, rule, board action and hearing in one list with its next clock

The clocks rail: comment deadlines and filing dates side by side

A rail on the front page shows every dated clock in the next 60 days with the days left: hearings, written comments, the Q3 lobbying report. Lena sees 9 days on the Colorado comments and 13 on the report without opening anything.

Below it, "Also in this edition" lists the rest of what moved, each item with its score and its next date, so a lead can scan them all at a glance.

A daily brief for each lead, and the weekly brief for leadership

Each lead gets only their issues. Omar's brief for October 7 has 6 items and 15 citations, arranged as act now and this week. Lena can untick an item, ask for another draft, preview the email, then approve and send. The FTC sample report scored 52, below the daily threshold of 55, so it waits for the weekly digest. The weekly leadership brief adds the numbers: 8,940 documents read, 2,106 matched, 23 high-impact alerts.

State activity on one map, by issue

Issue weights and how each issue reaches each medicine

Seven issues carry a weight, products, a lead and a lobbying code. Change a weight and every score updates. Under them, a grid agreed with market access and reviewed quarterly says how each issue reaches each medicine. A cell might read "Rebates with the 3 largest PBMs" or "Compound patent to 2035".

How much was read, how fast it reached the lead, and how often people disagreed

Six agents read and draft; a policy analyst confirms every score before an alert leaves

In shortEach agent has one job and a limit it cannot cross. Two rules are locked on: a person confirms every alert and brief, and each sentence quotes its passage. Government affairs operations approves the lobbying log; the system does not file anything.

The contact log that supports the quarterly lobbying report

When a lead records a contact with an official after an alert, the Disclosure Linker logs it and flags any entry with no code before the quarter closes. Treat this as an internal record. The LD-2 itself reports issues, the Houses and agencies contacted, the lobbyists and the spending (47). The sample log also lists a Michigan committee and Colorado board staff: those belong in state records, and your counsel decides what is reportable and where.

Enterprise controls: roles and separation of duties (analyst confirms, leads receive, operations approves the log), audit trail for each agent step, decision and settings change, versioned settings, audit export, and access by role. Information security is managed to ISO 27001 and audited under SOC 2 Type II. Sources are read-only, and originals are never changed.

Sources, issue lists and channel mix in; a front page, alerts and cited briefs out

In shortTwo kinds of input: public sources, and what only you know (your issues, weights, products and channel mix). The outputs are the front page, the path, alerts, briefs and the contact log. It sits beside the systems you already use, including any commercial tracker.

Works alongside what you already run: commercial bill and rule trackers, email and team chat, document stores, and the systems behind your lobbying filings. Ask us to show this on your own systems.

What the morning brief and a late catch cost your government affairs team

In shortYou have two costs: the steady one, analysts' hours spent reading and writing, and the rare one, the change that reached the lead too late. The first is easy to count. The second is why teams buy, and you will need your own examples to price it.

An estimate for one analyst on a mid-size manufacturer's watch list, 16.5 hours a week in all, at the calculator's illustrative rates in section 20, with no public benchmark behind it. Replace it with a one-week count of your own.

Six places policy tracking costs hide, and how to measure each in a week

What a government affairs budget line will never show

Your hours back on the morning brief: the value levers and a calculator for policy teams

In shortAnalyst hours are the part you can defend in a budget meeting. Avoided misses and outside spend matter too, yet they rest on your own judgment, so the calculator separates them. Every default is illustrative. Change them.

Five levers on legislative tracking software's value

Your yearly value from faster bill and rule reading

Formulas: time saved = analysts × (hours today − hours with automation) × weeks × hourly cost. Late catches = number avoided × your cost per catch. The 16.5 and 5.5 hours are estimates, about 11 hours a week back, with no public benchmark behind them; the rest are placeholders. Subtract the price of the tool and any overlap with what you already pay for. A cost per catch can be far larger or smaller than this default, depending on your exposure.

Is your policy team ready to automate tracking? Eight questions and one to think about

In shortScore each question 0, 1 or 2. A low score points to work worth doing before you buy anything, since automating a vague issue list gives you fast, vague answers. Nothing you choose leaves this page.

What your tracking readiness score suggests

What to ask a bill tracking or government affairs software vendor before you sign

In shortDemos always look good on the vendor's own bills. Ask these on your own issues and last month's real changes, and ask us too. The warning signs are claims about coverage with no list, and summaries with no quotation.

Testing tracking software on your own issues: eight weeks alongside the current brief

In shortPick one federal issue and one state issue, measure a baseline, then run both methods side by side, with your analyst confirming everything. If the new way misses less and saves time on your own changes, expand. If it does not, you still have a better baseline than you started with.

Seven numbers that show whether tracking automation is working

Legislative and regulatory tracking questions people ask most

In shortEach answer stands alone, with its date where it can change. Statuses are as of November 3, 2026.